Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Osvaldo Espin-Garcia is active.

Publication


Featured researches published by Osvaldo Espin-Garcia.


Nature Genetics | 2016

Association of host genome with intestinal microbial composition in a large healthy cohort

Williams Turpin; Osvaldo Espin-Garcia; Wei Xu; Mark S. Silverberg; David Kevans; Michelle I. Smith; David S. Guttman; Anne M. Griffiths; Remo Panaccione; Anthony Otley; Lizhen Xu; Konstantin Shestopaloff; Gabriel Moreno-Hagelsieb; Andrew D. Paterson; Kenneth Croitoru

Intestinal microbiota is known to be important in health and disease. Its composition is influenced by both environmental and host factors. Few large-scale studies have evaluated the association between host genetic variation and the composition of microbiota. We recruited a cohort of 1,561 healthy individuals, of whom 270 belong in 123 families, and found that almost one-third of fecal bacterial taxa were heritable. In addition, we identified 58 SNPs associated with the relative abundance of 33 taxa in 1,098 discovery subjects. Among these, four loci were replicated in a second cohort of 463 subjects: rs62171178 (nearest gene UBR3) associated with Rikenellaceae, rs1394174 (CNTN6) associated with Faecalibacterium, rs59846192 (DMRTB1) associated with Lachnospira, and rs28473221 (SALL3) associated with Eubacterium. After correction for multiple testing, 6 of the 58 associations remained significant, one of which replicated. These results identify associations between specific genetic variants and the gut microbiome.


PLOS ONE | 2013

Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis.

Qi Wang; Kangping Cui; Osvaldo Espin-Garcia; Dangxiao Cheng; Xiaoping Qiu; Zhuo Chen; Malcolm J. Moore; Robert G. Bristow; Wei Xu; Sandy Der; Geoffrey Liu

Background To establish, characterize and elucidate potential mechanisms of acquired bleomycin (BLM) resistance using human cancer cell lines. Seven BLM-resistant cell lines were established by exposure to escalating BLM concentrations over a period of 16-24 months. IC50 values and cell doubling times were quantified using a real time cytotoxicity assay. COMET and γ-H2AX assays, cell cycle analysis, and apoptosis assessment further investigated the mechanisms of BLM resistance in these cell lines. Results Compared with parental cell lines, real time cytotoxicity assays revealed 7 to 49 fold increases in IC50 and a mean doubling time increase of 147 % (range 64 %-352%) in BLM-resistant sub-clones (p<0.05 for both). Higher maintenance BLM concentrations were associated with higher IC50 and increased doubling times (p<0.05). Significantly reduced DNA damage (COMET and γ-H2AX assays), G2/M arrest, and apoptosis (p<0.05 for each set of comparison) following high-dose acute BLM exposure was observed in resistant sub-clones, compared with their BLM-sensitive parental counterparts. Three weeks of BLM-free culturing resulted in a partial return to BLM sensitivity in 3/7 BLM-resistant sub-clones (p<0.05). Conclusion Bleomycin resistance may be associated with reduced DNA damage after bleomycin exposure, resulting in reduced G2/M arrest, and reduced apoptosis.


PLOS ONE | 2015

Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers

Lorin Dodbiba; Jennifer Teichman; Andrew Fleet; Henry Thai; Maud H. W. Starmans; Roya Navab; Zhuo Chen; Hala Girgis; Lawson Eng; Osvaldo Espin-Garcia; Xiaowei Shen; Bizhan Bandarchi; Joerg Schwock; Ming-Sound Tsao; Hala El-Zimaity; Sandy Der; Wei Xu; Robert G. Bristow; Gail Darling; Paul C. Boutros; Laurie E. Ailles; Geoffrey Liu

The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing. The utility of primary tumor xenografts (PTXGs) as pre-clinical models was assessed. Clinicopathological, immunohistochemical markers (p53, p16, Ki-67, Her-2/neu and EGFR), and global mRNA abundance profiles were evaluated to determine selection biases of samples implanted or engrafted, compared with the underlying population. Nine primary E/GEJ adenocarcinoma xenograft lines were further characterized for the spectrum and stability of gene/protein expression over passages. Seven primary esophageal adenocarcinoma xenograft lines were treated with individual or combination chemotherapy. Tumors that were implanted (n=55) in NOD/SCID mice had features suggestive of more aggressive biology than tumors that were never implanted (n=32). Of those implanted, 21/55 engrafted; engraftment was associated with poorly differentiated tumors (p=0.04) and older patients (p=0.01). Expression of immunohistochemical markers were similar between patient sample and corresponding xenograft. mRNA differences observed between patient tumors and first passage xenografts were largely due to loss of human stroma in xenografts. mRNA patterns of early vs late passage xenografts and of small vs large tumors of the same passage were similar. Complete resistance was present in 2/7 xenografts while the remaining tumors showed varying degrees of sensitivity, that remained constant across passages. Because of their ability to recapitulate primary tumor characteristics during engraftment and across serial passaging, PTXGs can be useful clinical systems for assessment of drug sensitivity of human E/GEJ cancers.


International Journal of Cancer | 2016

BRM polymorphisms, pancreatic cancer risk and survival

Maja Segedi; Laura N. Anderson; Osvaldo Espin-Garcia; Ayelet Borgida; Teresa Bianco; Dangxiao Cheng; Zhuo Chen; Devalben Patel; M Catherine Brown; Wei Xu; David Reisman; Steven Gallinger; Michelle Cotterchio; Rayjean J. Hung; Geoffrey Liu; Sean P. Cleary

Variant alleles of two promoter polymorphisms in the BRM gene (BRM‐741, BRM‐1321), create MEF2D transcription binding sites that lead to epigenetic silencing of BRM, the key catalytic component of the SWI/SNF chromatin remodeling complex. BRM suppression can be reversed pharmacologically.1 Our group and others have reported associations with lung, head and neck, hepatocellular cancer risk,1–3 and with lung and esophageal cancer prognosis (ASCO 2013; abstract 11057 & 4077). Herein, we assessed risk and survival associations with pancreatic cancer. A provincial population‐based case‐control study was conducted with 623 histologically confirmed pancreatic adenocarcinoma cases and 1,192 age/gender distribution‐matched controls.4 Survival of cases was obtained through the Ontario Cancer Registry. Logistic and Cox proportional hazard regression models were fitted, adjusting for relevant covariates. Median age was 65 y; 52% were male; Stage I (8%), II (55%), III (14%), IV (23%); 53% after curative resection, 79% after chemotherapy; and 83% had died. In the risk analysis, adjusted odds ratios (aOR) were 1.01 (95% CI: 0.1–2.0) and 0.96 (95% CI: 0.7–1.3) for the homozygotes of BRM‐741 and BRM‐1321, respectively; aOR of double‐homozygotes was 1.11 (95% CI: 0.80–1.53), compared to the double‐wildtype. For the survival analysis, adjusted hazard ratios (aHR) were 2.19 (95% CI: 1.9–2.5) for BRM‐741 and 1.94 (95% CI: 1.7–2.2) for BRM‐1321, per unit increase in variant alleles. Compared with the double‐wildtype, aHR for carrying no, one, and two double‐homozygotes were 2.14 (95% CI: 1.6–2.8), 4.17 (95% CI: 3.0–5.7), 8.03 (95% CI: 5.7–11.4), respectively. In conclusion, two functional promoter BRM polymorphisms were not associated with pancreatic adenocarcinoma risk, but are strongly associated with survival.


Journal of Oncology Practice | 2015

Lifestyle Behaviors in Elderly Cancer Survivors: A Comparison With Middle-Age Cancer Survivors

Chongya Niu; Lawson Eng; Xin Qiu; Xiaowei Shen; Osvaldo Espin-Garcia; Yuyao Song; Dan Pringle; Mary Mahler; Oleksandr Halytskyy; Rebecca Charow; Christine Lam; Ravi M. Shani; Jodie Villeneuve; Kyoko Tiessen; M Catherine Brown; Peter Selby; Doris Howell; Jennifer M. Jones; Wei Xu; Geoffrey Liu; Shabbir M.H. Alibhai

PURPOSE Improved cancer screening and treatment have led to a greater focus on cancer survivorship care. Older cancer survivors may be a unique population. We evaluated whether older cancer survivors (age ≥ 65 years) had lifestyle behaviors, attitudes, and knowledge distinct from younger survivors. PATIENTS AND METHODS Adult cancer survivors with diverse cancer subtypes were recruited from Princess Margaret Cancer Centre (Toronto, Ontario, Canada). Multivariable models evaluated the effect of age on smoking, alcohol, and physical activity habits, attitudes toward and knowledge of these habits on cancer outcomes, and lifestyle information and recommendations received from health care providers, adjusted for sociodemographic and clinicopathologic covariates. RESULTS Among the 616 survivors recruited, 23% (n = 139) were older. Median follow-up since diagnosis was 24 months. Older survivors were more likely ex-smokers and less likely current smokers than younger survivors, but they were less likely to know that smoking could affect cancer treatment (adjusted odds ratio [OR], 0.53; P = .007) or prognosis (adjusted OR, 0.53; P = .008). Older survivors were more likely to perceive alcohol as improving overall survival (adjusted OR, 2.39; P = .02). Rates of meeting moderate-to-vigorous physical activity guidelines 1 year before diagnosis (adjusted OR, 0.55; P = .02) and maintaining and improving their exercise levels to meet these guidelines after diagnosis (adjusted OR, 0.48; P = .02) were lower in older survivors. Older and younger cancer survivors reported similar rates of receiving lifestyle behavior information from health care providers (P = .36 to .98). CONCLUSION Older cancer survivors reported being less aware of the impact of smoking on their overall health, more likely perceived alcohol as beneficial to survival, and were less likely to meet exercise goals compared with younger survivors. Survivorship programs need to consider age when counseling on lifestyle behaviors.


Gut microbes | 2018

FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects

Williams Turpin; L Bedrani; Osvaldo Espin-Garcia; Wei Xu; Mark S. Silverberg; Michelle I. Smith; David S. Guttman; Anne M. Griffiths; Paul Moayyedi; Remo Panaccione; Hien Q. Huynh; Hillary Steinhart; Guy Aumais; Konstantin Shestopaloff; Levinus A. Dieleman; Dan Turner; Andrew D. Paterson; Kenneth Croitoru

ABSTRACT Heritability analysis of the microbiota has demonstrated the importance of host genotype in defining the human microbiota. The alpha (1,2)-fucosyltransferase 2 encoded by FUT2 is involved in the formation of the H antigen and the SNP, rs601338 is associated with ABO histo-blood group antigen secretion in the intestinal mucosa. Previous studies have provided non replicated results for the association of this polymorphism with the composition and inferred function of intestinal microbiota. We aimed to assess this relationship in a large cohort of 1,190 healthy individuals. Genotyping was performed using the HumanCoreEXOME chip, microbial composition was addressed by 16S rRNA gene sequencing. Firmicutes, Bacteroidetes, and Actinobacteria were the dominant phyla in this cohort. Although we have sufficient power to detect significant associations of FUT2 genotype/ inferred phenotype with the microbiota, our data demonstrate that FUT2 genotype and secretor status is not associated with microbial alpha diversity, microbial composition or inferred microbial function after correction for multiple testing. Thus, FUT2 genotype and inferred phenotype are not associated with human fecal microbial composition and imputed function.


Journal of Thoracic Oncology | 2016

Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma

Harvey I. Pass; Chandra Goparaju; Osvaldo Espin-Garcia; Jessica S. Donington; Michele Carbone; Devalben Patel; Zhuo Chen; Ronald Feld; J. Cho; Shirish M. Gadgeel; Antoinette J. Wozniak; Abraham Chachoua; Natasha B. Leighl; Ming-Sound Tsao; Marc de Perrot; Wei Xu; Geoffrey Liu

Objectives: Prognostic models for malignant pleural mesothelioma (MPM) are needed to prevent potentially futile outcomes. We combined MPM plasma biomarkers with validated clinical prognostic indices to determine whether stratification of risk for death in 194 patients with MPM improved. Methods: Individuals were recruited from three different centers: a discovery cohort (83 patients with MPM) created by combining patients from two U.S. centers and a separate, independent cohort from Canada (111 patients with MPM). Univariable and multivariable analyses were performed on the initial discovery and independent cohorts separately. In the multivariable analyses, prognostic factors were adjusted for the European Organisation for Research and Treatment of Cancer (EORTC) prognostic index (PI) of mesothelioma. The prognostic significance of adding plasma biomarker data to the PI was determined by using the likelihood ratio test, comparing models with and without the addition of biomarker to the clinical PI. The predictive ability of the biomarker was then assessed formally using Harrells C‐index by applying the fitted model variables of the discovery cohort to the second, independent cohort, including and not including the biomarker with the PI. Results: Higher levels of osteopontin and mesothelin were individually associated with worse prognosis after adjusting for the PI. In the independent cohort, incorporating either plasma osteopontin or mesothelin into the baseline predictive PI model substantively and statistically significantly improved Harrells C‐statistic. In the final prognostic model, log‐osteopontin, EORTC clinical prognostic index, and hemoglobin remained as independently significant predictors and the entire prognostic model improved the optimism‐corrected Harrells C‐index significantly, from 0.718 (0.67–0.77) to 0.801 (0.77–0.84). Conclusions: These data suggest a possible role for preoperative plasma biomarkers to improve the prognostic capability of the EORTC PI of MPM.


BMC Proceedings | 2014

Genetic association analysis for common variants in the Genetic Analysis Workshop 18 data: a Dirichlet regression approach

Osvaldo Espin-Garcia; Xiaowei Shen; Xin Qiu; Yonathan Brhane; Geoffrey Liu; Wei Xu

We propose a genetic association analysis using Dirichlet regression to analyze the Genetic Analysis Workshop 18 data. Clinical variables, arranged in a longitudinal data structure, are employed to fit a multistate transition model in which the transition probabilities are served as a response in the proposed analysis. Furthermore, a gene-based association analysis via penalized regression is implemented using the markers at a single-nucleotide polymorphism level that we previously identified via nonpenalized Dirichlet regression.


BMC Proceedings | 2014

Genetic association analysis using weighted false discovery rate approach on Genetic Analysis Workshop 18 data

Xin Qiu; Xiaowei Shen; Osvaldo Espin-Garcia; Abul Kalam Azad; Geoffrey Liu; Wei Xu

In a genome-wide association study, association between disease trait and hundreds of thousands of genetic markers are tested. Several methods have been proposed to control the false discovery rate in such high-throughput data to adjust for multiple hypotheses testing. For Genetic Analysis Workshop 18, we applied the method of false discovery rate control with p value weighting on family-based association tests on quantitative trait to detect association between single-nucleotide polymorphisms (SNPs) and mean arterial pressure. This method can improve statistical power by incorporating independent but relevant information about the research objective. Using the real genetic and phenotype data of chromosome 3 from Genetic Analysis Workshop 18, 1 SNP from gene CACNA2D3 was found to have significant association with mean arterial pressure.


PLOS ONE | 2018

Hedgehog inhibition mediates radiation sensitivity in mouse xenograft models of human esophageal adenocarcinoma

Jennifer Teichman; Lorin Dodbiba; Henry Thai; Andrew Fleet; Trevor Morey; Lucy Liu; Madison McGregor; Dangxiao Cheng; Zhuo Chen; Gail Darling; Yonathan Brhane; Yuyao Song; Osvaldo Espin-Garcia; Wei Xu; Hala Girgis; Joerg Schwock; Helen Mackay; Robert E. Bristow; Laurie Ailles; Geoffrey Liu

Background The Hedgehog (Hh) signaling pathway is active in esophageal adenocarcinoma (EAC). We used a patient-derived murine xenograft (PDX) model of EAC to evaluate tumour response to conventional treatment with radiation/chemoradiation with or without Hh inhibition. Our goal was to determine the potential radioresistance effects of Hh signaling and radiosensitization by Hh inhibitors. Methods PDX models were treated with radiation, chemotherapy or combined chemoradiation. Tumour response was measured by growth delay. Hh transcript levels (qRT-PCR) were compared among frozen tumours from treated and control mice. 5E1, a monoclonal SHH antibody, or LDE225, a clinical SMO inhibitor (Novartis®) inhibited Hh signaling. Results Precision irradiation significantly delayed xenograft tumour growth in all 7 PDX models. Combined chemoradiation further delayed growth relative to either modality alone in three of six PDX models. Following irradiation, two of three PDX models demonstrated sustained up-regulation of Hh transcripts. Combined LDE225 and radiation, and 5E1 alone delayed growth relative to either treatment alone in a Hh-responsive PDX model, but not in a non-responsive model. Conclusion Hh signaling mediates the radiation response in some EAC PDX models, and inhibition of this pathway may augment the efficacy of radiation in tumours that are Hh dependent.

Collaboration


Dive into the Osvaldo Espin-Garcia's collaboration.

Top Co-Authors

Avatar

Geoffrey Liu

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Wei Xu

Nanjing Normal University

View shared research outputs
Top Co-Authors

Avatar

Wei Xu

Nanjing Normal University

View shared research outputs
Top Co-Authors

Avatar

Lawson Eng

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Devalben Patel

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Zhuo Chen

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Doris Howell

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Dangxiao Cheng

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Xiaowei Shen

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Catherine Brown

Princess Margaret Cancer Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge